Published by Josh White on 26th July 2024
(Sharecast News) - AstraZeneca's 'Imfinzi', or durvalumab, was recognised by the FDA's oncologic drugs advisory committee (ODAC) on Friday for its efficacy in treating resectable non-small cell lung cancer (NSCLC), based on phase three trial results.
URL: http://www.digitallook.com/dl/news/story/34452940/...